1. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability;Amidon;Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci.,1995
2. EMA - Committee for Medicinal Products for Human Use (CHMP), Guideline on the investigation of bioequivalence, 1997. http://www.ema.europa.eu (accessed January 16, 2020).
3. FDA, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Guidance for Industry, 2017. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm (accessed January 16, 2020).
4. FDA, Guidance for Industry - Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations, Tel, 1997. http://www.fda.gov/cder/guidance/index.htm (accessed January 16, 2020).
5. EMA - Committee for Medicinal Products for Human Use (CHMP), Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1), 2014. http://www.ema.europa.eu/contact (accessed January 16, 2020).